Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Nuformix Plc (NFX) Share Price & Analysis

NFX Stock Chart & Stats

GBX 0.11GBX 0.00(0.00%)
At close: 4:30 PM GMT
GBX 0.1GBX 0.125GBX 0.15GBX 0.1753 Aug17 Aug1 Sep14 Sep28 Sep12 Oct26 Oct
Day’s Range
GBX 0.10 - GBX 0.11
52-Week Range
GBX 0.09 - GBX 0.56
Previous Close
GBX 0.11
Volume
3.57M
Average Volume (3M)
19.79M
Market Cap
GBP 2.74M
Enterprise Value
GBP 2.97T
Total Cash (Recent Filing)
GBP 930.28K
Total Debt (Recent Filing)
GBP 0
Price to Earnings (P/E)
―
Beta
-0.23
Next Earnings
Feb 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of debt limits interest obligations and refinancing exposure, giving Nuformix greater flexibility while it develops its pipeline. Although the balance sheet is small, a debt-free structure can help preserve strategic options and reduce fixed financial pressure over the next several quarters.

Proprietary Inhaled Drug Development

A focus on inhaled formulations and repurposed drugs gives Nuformix a defined development approach in respiratory medicine. Improving delivery to the lungs while reducing systemic exposure could provide meaningful product differentiation if the candidates demonstrate clinical and regulatory value.

Partnering-based Monetization Model

A partnering-led model can allow Nuformix to pursue commercialization without building large-scale manufacturing and sales infrastructure. If candidates progress, upfront payments, milestones, and royalties could create several potential value-creation routes while limiting the need for substantial internal commercial investment.

Bears Say

No Recent Revenue

The absence of reported revenue across three recent annual periods indicates that Nuformix has not yet established a meaningful commercial revenue base. This leaves the company dependent on future development success, partnering transactions, or other funding rather than recurring operating income.

Persistent Cash Burn

Persistent negative operating and free cash flow shows that the business continues to consume cash rather than fund itself through operations. Ongoing burn can constrain development activity and increase reliance on external funding, making execution and capital availability important over the next several quarters.

Shrinking Financial Buffer

The substantial reduction in equity and assets indicates that cumulative losses or balance-sheet actions have materially reduced Nuformix’s financial base. Even without debt, a smaller asset cushion leaves less capacity to absorb setbacks and may limit the resources available for pipeline development.

Nuformix Plc News

NFX FAQ

What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.09 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £2.74M.
When is Nuformix Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported 0 p earnings per share for the quarter.
Is Nuformix Plc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of 0 p in its last earnings report. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology